EXCERPT:
Researchers have published an alternative CAR-T manufacturing approach using a protein scaffold linking IL-7, IL-15, and IL-21. The resulting cells show improved survival, maintained effector function, and self-renewal capacity — potentially addressing one of CAR-T’s biggest clinical limitations.
CONTENT:
A new manufacturing approach for CAR-T cells has been published that may address one of the field’s most persistent clinical problems: T cell exhaustion and loss of persistence after infusion.
The method uses a protein scaffold engineered to link three cytokines — IL-7, IL-15, and IL-21 — that are known to promote T cell survival and immune memory. CAR-T cells manufactured using this scaffold demonstrated longer survival, maintained disease-fighting function, and showed self-renewal capacity in preclinical models.
If these results translate clinically, the implications are significant. T cell exhaustion is a primary driver of relapse in CAR-T treated patients, particularly in solid tumor settings where the antigen burden is high and the tumor microenvironment is suppressive. A manufacturing intervention that builds persistence into the product from the start is a fundamentally different approach than post-infusion cytokine support strategies.
From a manufacturing standpoint, the key question is whether the scaffold approach is scalable and compatible with existing closed-system manufacturing platforms. That’s where CRO and CDMO involvement becomes critical in moving from publication to clinical translation.